Last reviewed · How we verify
CD276 CAR-T cells
At a glance
| Generic name | CD276 CAR-T cells |
|---|---|
| Sponsor | Shenzhen University General Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- B7-H3.CD28Z.CART in CNS Neoplasms (PHASE1)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (PHASE1, PHASE2)
- Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme (PHASE1)
- WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients (EARLY_PHASE1)
- CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor (EARLY_PHASE1)
- TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |